ROQ vs. BVX, APTA, OBD, CIZ, HEMO, FAB, BSFA, EVG, GENF, and MTFB
Should you be buying Roquefort Therapeutics stock or one of its competitors? The main competitors of Roquefort Therapeutics include BiVictriX Therapeutics (BVX), Aptamer Group (APTA), Oxford BioDynamics (OBD), Cizzle Biotechnology (CIZ), Hemogenyx Pharmaceuticals (HEMO), Fusion Antibodies (FAB), BSF Enterprise (BSFA), Evgen Pharma (EVG), Genflow Biosciences (GENF), and Motif Bio (MTFB). These companies are all part of the "biotechnology" industry.
Roquefort Therapeutics vs.
Roquefort Therapeutics (LON:ROQ) and BiVictriX Therapeutics (LON:BVX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings, community ranking and profitability.
Roquefort Therapeutics has higher revenue and earnings than BiVictriX Therapeutics. Roquefort Therapeutics is trading at a lower price-to-earnings ratio than BiVictriX Therapeutics, indicating that it is currently the more affordable of the two stocks.
Roquefort Therapeutics and BiVictriX Therapeutics both received 0 outperform votes by MarketBeat users.
In the previous week, Roquefort Therapeutics had 1 more articles in the media than BiVictriX Therapeutics. MarketBeat recorded 1 mentions for Roquefort Therapeutics and 0 mentions for BiVictriX Therapeutics. BiVictriX Therapeutics' average media sentiment score of 0.00 beat Roquefort Therapeutics' score of -1.29 indicating that BiVictriX Therapeutics is being referred to more favorably in the news media.
Roquefort Therapeutics has a beta of 0.05, suggesting that its share price is 95% less volatile than the S&P 500. Comparatively, BiVictriX Therapeutics has a beta of -0.73, suggesting that its share price is 173% less volatile than the S&P 500.
BiVictriX Therapeutics has a net margin of 0.00% compared to Roquefort Therapeutics' net margin of -57,057.07%. Roquefort Therapeutics' return on equity of -29.57% beat BiVictriX Therapeutics' return on equity.
1.7% of Roquefort Therapeutics shares are held by institutional investors. Comparatively, 30.8% of BiVictriX Therapeutics shares are held by institutional investors. 60.4% of Roquefort Therapeutics shares are held by company insiders. Comparatively, 42.6% of BiVictriX Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Roquefort Therapeutics beats BiVictriX Therapeutics on 8 of the 12 factors compared between the two stocks.
Get Roquefort Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ROQ and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Roquefort Therapeutics Competitors List
Related Companies and Tools
This page (LON:ROQ) was last updated on 5/3/2025 by MarketBeat.com Staff
Buy ROQ Stock Free ROQ Stock Alerts